Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Systematic review: does endocrine therapy prolong survival in patients with prostate cancer?

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Development and validation of a simulator-based test in transurethral resection of bladder tumours (TURBEST)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Educational level and first-time PSA testing in general practice

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Robotic versus laparoscopic urological surgery: incidence of reoperation and complications

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Successful extraction of sperm cells after autologous bone marrow transplant: a case report

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Community-based football in men with prostate cancer: 1-year follow-up on a pragmatic, multicentre randomised controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Educational level and first-time PSA testing in general practice

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Palliative Prostate Artery Embolization for Prostate Cancer: A Case Series

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Predictive value of AZGP1 following radical prostatectomy for prostate cancer: a cohort study and meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Objective Primary androgen deprivation therapy (ADT) remains the gold standard in the management of patients with advanced prostate cancer (PCa). ADT relieves symptoms and reduces tumor burden, but it has never been demonstrated to increase either PCa-specific or overall survival per se. Several trials have challenged this dogma. The aim of this study was to evaluate how endocrine therapy (ET) affects survival in different clinical settings of PCa. Materials and methods A review of published phase II, III and IV studies evaluating the effect of ET on survival was performed. Results In localized and locally advanced non-metastatic PCa, neoadjuvant ET before radical prostatectomy has no effect on survival. Neoadjuvant and adjuvant ET in combination with curatively intended radiotherapy results in PCa-specific and overall survival benefit, although the duration of ET remains under debate. In N + disease, the timing of ET is under debate, although data suggest that early ET is associated with decreased PCa-specific and overall mortality. In M + disease, no proper randomized trials have been performed in patients with newly diagnosed M1 disease. In metastatic castration-resistant PCa, two novel endocrine agents have been proven to increase overall survival significantly compared to placebo. Conclusions ET has never been proven to increase survival in newly diagnosed metastatic PCa in a randomized clinical trial. Nonetheless, a number of trials supports that ET with proper timing, sequencing and in combination with other therapeutic modalities increases survival in several stages of PCa.

OriginalsprogEngelsk
TidsskriftScandinavian Journal of Urology and Nephrology
Vol/bind50
Udgave nummer3
Sider (fra-til)135-43
Antal sider9
ISSN0036-5599
DOI
StatusUdgivet - jun. 2016

ID: 46295562